SY001 + tislelizumab

SY001 + tislelizumab is a combination therapy under investigation. **SY001** is an experimental drug targeting **mesothelin**, a cell surface glycoprotein highly expressed in several cancers, notably ovarian cancer. **Tislelizumab** is a humanized IgG4 monoclonal antibody against programmed death-1 (**PD-1**) designed to block the PD-1/PD-L1 immune checkpoint pathway, thus enhancing antitumor immunity. The combination is being studied primarily in the context of **mesothelin-positive ovarian cancer**, with administration of SY001 alongside tislelizumab (an anti–PD-1 monoclonal antibody). This combination aims to leverage direct antitumor activity through mesothelin targeting (by SY001) and immune checkpoint blockade (by tislelizumab), potentially providing synergistic effects in immunotherapy. The specific mechanisms, efficacy, and clinical development status for this combination are based on ongoing early-phase clinical trials.